BJC Capital Advisors
The evolution of the biopharmaceutical industry has witnessed the disaggregation of the industry value chain. Today, emerging companies in the sector may be best characterized as an outsourced R&D function for the large pharmaceutical companies, who leverage their established regulatory and commercialization engines to optimize externally sourced innovation. In such a scenario, the intrinsic value of infrastructure, both physical and intellectual, is often minimized and may arguably be considered detracting. BJC Capital Advisors, a FINRA registered broker/dealer, was established to complement these sector trends with professional services designed to enhance capital efficiency and value realization.
Founding Managing Director
Benjamin Conway has over 25 years of experience in investment banking with transaction experience involving mergers & acquisitions, public and private equity financings and strategic partnerships across an array of sectors including biotechnology, specialty pharmaceuticals, medical device, diagnostics and the ancillary services sectors. Prior to founding the firm, he was managing director and head of the life sciences practice at Boston-based Consilium Partners. Previously, Ben was with Johnston Blakely & Company, a boutique life science investment bank he founded in 2002 which was subsequently acquired by Germany’s CMC Consulting. Ben was group head of biotechnology investment banking at Adams, Harkness & Hill, a Boston-based investment bank and his experience includes positions with Abbott Laboratories and Bain & Company. Ben received an M.B.A., with honors, from the Harvard Business School and an A.B., magna cum laude, from Bowdoin College. He holds FINRA Series 7, 24, 63, 79 and 28 licenses.
BJC Capital Advisors LLC